MARKET

PTCT

PTCT

PTC Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

57.10
+1.91
+3.46%
After Hours: 57.10 0 0.00% 16:06 02/26 EST
OPEN
54.41
PREV CLOSE
55.19
HIGH
57.68
LOW
54.00
VOLUME
972.41K
TURNOVER
--
52 WEEK HIGH
70.82
52 WEEK LOW
30.79
MARKET CAP
3.90B
P/E (TTM)
-8.3079
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
PTC Therapeutics (PTCT) Receives a Buy from Raymond James
Raymond James analyst Danielle Brill maintained a Buy rating on PTC Therapeutics (PTCT) yesterday and set a price target of $70.00. The company's shares
SmarterAnalyst · 8h ago
PTC Therapeutics' Evrysdi wins positive opinion in EU for spinal muscular atrophy
The European Medicines Agency's advisory group has recommended the approval of PTC Therapeutics' (PTCT) Evrysdi (risdiplam) for the treatment of 5q spinal muscular atrophy ((SMA)) in patients 2 months and older.The
Seekingalpha · 8h ago
BRIEF-CHMP Adopts Positive Opinion For Evrysdi For The Treatment Of Spinal Muscular Atrophy
reuters.com · 9h ago
CHMP Adopts Positive Opinion for Evrysdi™ for the Treatment of Spinal Muscular Atrophy in Adults and Children Aged Two Months and Older
, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Evrysdi™ (risdiplam) for the treatment of 5q spinal mus...
PR Newswire - PRF · 9h ago
PTC Therapeutics (PTCT) Receives a Buy from William Blair
SmarterAnalyst · 19h ago
BRIEF-PTC Therapeutics Reports Q4 Total Rev Of $118.9 Mln
reuters.com · 23h ago
8-K: PTC THERAPEUTICS, INC.
Edgar Online - (EDK = 8-Ks/S1/S-4) · 23h ago
10-K: PTC THERAPEUTICS, INC.
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. The following discussion of our...
Edgar Online - (EDG = 10Q, 10K) · 23h ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PTCT. Analyze the recent business situations of PTC Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PTCT stock price target is 66.50 with a high estimate of 90.00 and a low estimate of 47.00.
EPS
Institutional Holdings
Institutions: 340
Institutional Holdings: 75.26M
% Owned: 110.29%
Shares Outstanding: 68.24M
TypeInstitutionsShares
Increased
63
3.29M
New
59
589.38K
Decreased
80
2.26M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.37%
Pharmaceuticals & Medical Research
-0.85%
Key Executives
Chairman/Independent Director
Michael Schmertzler
Chief Executive Officer/Director
Stuart Peltz
Chief Financial Officer/Treasurer
Emily Hill
Chief Operating Officer
Marcio Souza
Executive Vice President
Mark Boulding
Senior Vice President - Finance/Chief Accounting Officer
Christine Utter
Other
Neil Almstead
Other
Matthew Klein
Other
Eric Pauwels
Independent Director
Allan Jacobson
Independent Director
Stephanie Okey
Independent Director
Emma Reeve
Independent Director
David Southwell
Independent Director
Glenn Steele
Independent Director
Dawn Svoronos
Independent Director
Jerome Zeldis
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About PTCT
PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. The Company have a portfolio pipeline that includes commercial products as well as product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The Company have two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). The Company have a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS), including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC) and PTC923 for phenylketonuria (PKU) diseases.

Webull offers kinds of PTC Therapeutics, Inc. stock information, including NASDAQ:PTCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTCT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTCT stock methods without spending real money on the virtual paper trading platform.